Replimune to Present at the 2025 Jefferies Global Healthcare Conference
Replimune Group (NASDAQ: REPL), a clinical-stage biotech company focused on developing novel oncolytic immunotherapies, has announced its participation in the 2025 Jefferies Global Healthcare Conference. The company's management team will engage in a fireside chat on June 5, 2025, at 4:20 PM ET. Investors can access the live webcast through Replimune's website investor section, with a replay available for 30 days after the event.
Replimune Group (NASDAQ: REPL), un'azienda biotecnologica in fase clinica specializzata nello sviluppo di nuove immunoterapie oncolitiche, ha annunciato la sua partecipazione alla Jefferies Global Healthcare Conference 2025. Il team di gestione dell'azienda parteciperà a una conversazione informale il 5 giugno 2025, alle 16:20 ET. Gli investitori potranno seguire la diretta streaming nella sezione investitori del sito web di Replimune, con la possibilità di rivedere la registrazione per 30 giorni dopo l'evento.
Replimune Group (NASDAQ: REPL), una empresa biotecnológica en etapa clínica enfocada en el desarrollo de nuevas inmunoterapias oncolíticas, ha anunciado su participación en la Conferencia Global de Salud Jefferies 2025. El equipo directivo de la compañía participará en una charla informal el 5 de junio de 2025, a las 4:20 PM ET. Los inversores podrán acceder a la transmisión en vivo a través de la sección de inversores del sitio web de Replimune, con una repetición disponible durante 30 días después del evento.
Replimune Group (NASDAQ: REPL)은 혁신적인 온콜리틱 면역치료제 개발에 주력하는 임상 단계의 바이오텍 회사로, 2025년 Jefferies 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2025년 6월 5일 오후 4시 20분 ET에 화상 토론에 참여할 예정입니다. 투자자들은 Replimune 웹사이트 투자자 섹션을 통해 생중계에 접속할 수 있으며, 행사가 끝난 후 30일 동안 다시보기 서비스를 이용할 수 있습니다.
Replimune Group (NASDAQ : REPL), une entreprise biotechnologique en phase clinique spécialisée dans le développement de nouvelles immunothérapies oncolytiques, a annoncé sa participation à la Jefferies Global Healthcare Conference 2025. L'équipe de direction de la société participera à une discussion informelle le 5 juin 2025 à 16h20 ET. Les investisseurs pourront accéder à la diffusion en direct via la section investisseurs du site Web de Replimune, avec une rediffusion disponible pendant 30 jours après l'événement.
Replimune Group (NASDAQ: REPL), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung neuartiger onkolytischer Immuntherapien spezialisiert hat, hat seine Teilnahme an der Jefferies Global Healthcare Conference 2025 angekündigt. Das Management-Team des Unternehmens wird am 5. Juni 2025 um 16:20 Uhr ET an einem Gespräch teilnehmen. Investoren können den Live-Webcast über den Investor-Bereich der Replimune-Website verfolgen, mit einer Wiederholung, die 30 Tage nach der Veranstaltung verfügbar ist.
- None.
- None.
WOBURN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 4:20 PM ET.
A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be available for 30 days following the conference.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Investor Inquiries
Chris Brinzey
ICR Healthcare
339.970.2843
chris.brinzey@icrhealthcare.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
FAQ
When is Replimune (REPL) presenting at the 2025 Jefferies Healthcare Conference?
How can investors watch Replimune's (REPL) presentation at the Jefferies conference?
What type of company is Replimune (REPL)?
What is the format of Replimune's (REPL) presentation at the Jefferies conference?
